B
Regeneron Pharmaceuticals, Inc. REGN
$1,150.19 $11.381.00%
Recommendation
Buy
Prev Close
$1,138.81
Volume
596,685
Avg Vol (90D)
438,474
Market Cap
$122.92B
Dividend & Yield
--
52-Week Range
$769.19 - $1,211.20
P/E (TTM)
30.16
EPS (TTM)
$37.76
My Lists My Alerts
Report
Rating
Reward
B
Good
Risk
B-
Good
Rating Factors
Growth Index
Fair
Efficiency Index
Excellent
Solvency Index
Excellent
Total Return Index
Good
Volatility Index
Good
Dividend Index
--
Headlines
Mark Sheptoff Financial Planning LLC Has $142,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/19/2024 - Zolmax
Mark Sheptoff Financial Planning LLC Has $142,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/19/2024 - Ticker Report
Kendall Capital Management Has $2.54 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/19/2024 - Ticker Report
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Mercer Global Advisors Inc. ADV
9/19/2024 - Ticker Report
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
9/19/2024 - Zacks Investment Research
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Paces Ferry Wealth Advisors LLC
9/19/2024 - Ticker Report
Argent Trust Co Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/19/2024 - Zolmax
Argent Trust Co Has $2.49 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/19/2024 - Ticker Report
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Royal Bank of Canada
9/19/2024 - Zolmax
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Royal Bank of Canada
9/19/2024 - Ticker Report
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
9/18/2024 - Zacks Investment Research
OMFL, MCK, CRM, REGN: Large Outflows Detected at ETF
9/18/2024 - ETF Channel
Brown Brothers Harriman & Co. Has $509,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/18/2024 - Ticker Report
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
9/18/2024 - Zacks Investment Research
Cantor Fitzgerald Reaffirms Neutral Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)
9/18/2024 - Ticker Report
Jim Cramer Says Regeneron Pharmaceuticals Inc. (REGN)'s Oncology Portfolio is Beautiful
9/17/2024 - Insider Monkey
Massachusetts Financial Services Co. MA Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/17/2024 - Zolmax
Massachusetts Financial Services Co. MA Buys 59,769 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/17/2024 - Ticker Report
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wealthspire Advisors LLC
9/17/2024 - Ticker Report
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wealthspire Advisors LLC
9/17/2024 - Zolmax
Thoroughbred Financial Services LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/17/2024 - Ticker Report
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by J.W. Cole Advisors Inc.
9/17/2024 - Ticker Report
Thoroughbred Financial Services LLC Purchases Shares of 490 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/17/2024 - Zolmax
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
9/16/2024 - Zacks Investment Research
Parallel Advisors LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
9/16/2024 - Zolmax
Income Statement
Total Revenue (TTM)
$13.49B
EBITDA (TTM)
$4.52B
EBIT (TTM)
$4.07B
Net Income (TTM)
$4.32B
Balance Sheet
Total Assets (Q)
$36.09B
Total Debt (Q)
$2.70B
Total Liabilities (Q)
$7.88B
Book Value Per Share (Q)
$261.41
Cash Flow
Cash from Operations (TTM)
$4.07B
Cash from Investing (TTM)
-$2.81B
Cash from Financing (TTM)
-$1.28B
Net Change in Cash (TTM)
-$21.50M
Filings
Filing Date
Thursday, August 1, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Beginning of November (est)
Price History
Loading...
Beta
0.42
7-Day Total Return
1.22%
30-Day Total Return
7.72%
60-Day Total Return
7.37%
90-Day Total Return
18.11%
Year to Date Total Return
27.09%
1-Year Total Return
37.46%
2-Year Total Return
60.79%
3-Year Total Return
79.47%
5-Year Total Return
301.95%
52-week Low
Oct 27, 2023 - $769.19
52-week High
Aug 27, 2024 - $1,211.20
Valuation
Market Cap
$122.92B - Large Cap
Enterprise Value
$108.09B
Price/Sales (TTM)
9.74
Price/Book (Q)
4.36
Dividends and Shares
Shares Outstanding
115.40M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.regeneron.com
Phone Number
914 847 7000
Address
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Country
United States
Year Founded
1988
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to... more
NASDAQ 09/19/2024 4:00PM Eastern Quotes delayed
Weiss Ratings